CASI Falls 2% Even as Chinese Regulator Schedules Meeting for Review

CASI Pharmaceuticals (CASI) shares dropped 2% on Thursday afternoon even after the company said it got a letter from the Center for Drug Evaluation (CDE), a group within China’s drugs regulator in charge of technical review, indicating that Evomela for injection has been scheduled for review by the Expert Advisory Anti-Tumor Drugs Committee.

The meeting will take place between April 25-26, it said.

No additional information on the application has been requested by the CDE in advance of the Advisory Committee Meeting, however, CASI will submit a Clinical Data Briefing Package which will summarize the various components contained in the previously submitted application, the company said.

Leave a Reply

Your email address will not be published. Required fields are marked *